Tissue Therapies patent accepted in Australia
Tuesday, 31 May, 2005
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
The acceptance follows the granting of the core VitroGro patent in New Zealand in March, the first jurisdiction to do so.
Tissue Therapies has worldwide exclusive rights to commercialise VitroGro under an IP Agreement with the Queensland University of Technology, and will also seek core patents for VitroGro in other jurisdictions such as the USA, Canada, Europe, South Korea, China and Japan.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
